Tag: Symic Bio
Phase I/II SHIELD trial results with SB-030 in peripheral vascular disease...
Symic Bio has announced results from the phase I/II SHIELD trial evaluating SB-030, a locally administered therapeutic, in patients with peripheral vascular disease undergoing...
Last patient enrolled in SB-030 SHIELD trial for peripheral artery disease...
Symic Bio, has completed enrolment for the SHIELD clinical trial of SB-030 in peripheral artery disease. The trial will evaluate the safety and efficacy...